Economic Evaluation of Universal Varicella Vaccination in Mexico
- PMID: 34966138
- PMCID: PMC8997664
- DOI: 10.1097/INF.0000000000003448
Economic Evaluation of Universal Varicella Vaccination in Mexico
Abstract
Background: Universal varicella vaccination has proven to be cost-effective (CE) in countries where implemented. However, this has not been evaluated for Mexico.
Methods: The yearly disease burden (varicella cases/deaths, outpatient visits, and hospitalizations) was derived from Mexican seroprevalence data adjusted to the 2020 population. The yearly economic burden was calculated by combining disease with Mexican unit cost data from both health care and societal perspectives. Four different vaccination strategies were evaluated: (1) 1 dose of varicella vaccine at 1 year old; (2) 2 doses at 1 and 6 years; (3) 1 dose of varicella vaccine at 1 year, and quadrivalent measles-mumps-rubella-varicella vaccine at 6 years; (4) 2 doses of measles-mumps-rubella-varicella vaccine at 1 and 6 years. We developed an economic model for each vaccination strategy where 20 consecutive birth cohorts were simulated. Vaccination impact (number of avoided cases/deaths) was evaluated for a 20-year follow-up period based on vaccine effectiveness (87% and 97.4% for 1 and 2 doses), and assuming a 95% coverage. We estimated annual costs saved, incremental cost-effectiveness ratio, and costs per life year gained.
Results: Avoided cases during the 20-year follow-up with 1, and 2 doses were 20,570,722 and 23,029,751, respectively. Strategies 1 and 2 were found to be cost saving, and strategy 3 to be CE. Strategy 4 was not CE. Strategies 1 and 2 would allow saving annually $53.16 and $34.41 million USD, respectively, to the Mexican society.
Conclusions: Universal varicella vaccination, using 1 dose or 2 doses, would result in a cost-beneficial and CE public health intervention in Mexico.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding or conflicts of interest to disclose.
Figures
References
-
- Meyer PA, Seward JF, Jumaan AO, et al. . Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis. 2000;182:383–390. - PubMed
-
- Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. Clin Infect Dis. 1996;23:698–705. - PubMed
-
- Chacon-Cruz E, Lopatynsky-Reyes E, Lopez-Martinez DA, et al. . Varicella hospitaizations and community-acquired Staphylococcus aureus infection: seven years of active surveillance. Ann Clin Lab Res. 2021; 9:354.
-
- World Health Organization. Summary of WHO position papers—Recommended Immunizations for Children [WHO website]. September 2020. Available at: https://www.who.int/immunization/policy/Immunization_routine_table 2.pdf. Accessed August 4, 2021.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
